Skip to main
MDXH

MDxHealth SA (MDXH) Stock Forecast & Price Target

MDxHealth SA (MDXH) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

MDxHealth is a company operating in the healthcare sector, providing molecular diagnostic information for personalized cancer treatment. Despite announcing a lower revenue forecast for 2026, the company is still recommended as a buy with a lowered price target due to its success in acquiring new tests and increased productivity. With a track record of successful acquisitions and strong revenue growth, MDxHealth is positioned for continued success in the urology market.

Bears say

MDxHealth is facing multiple challenges, such as a weaker-than-expected Q1'26 performance, a potential recoupment payment of $10 million related to its Resolve UTI test, and the decision to discontinue the test and shut down the TX lab, leading to a reduction in revenue estimates for 2026 and 2027. Additionally, while the company has acquired the ExoDx test, generating $20 million in annual revenue, it will take time to contribute to the company's bottom line. The company's tight cash flow and high debt levels also pose a risk, as does its dependence on government funding for research and development. Given these issues, the stock has seen a ~35% decline and a lowered price target from $7 to $4.

MDxHealth SA (MDXH) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MDxHealth SA (MDXH) Forecast

Analysts have given MDxHealth SA (MDXH) a Strong Buy based on their latest research and market trends.

According to 3 analysts, MDxHealth SA (MDXH) has a Strong Buy consensus rating as of Jun 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MDxHealth SA (MDXH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.